Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib Sequential to Chemoradiotherapy in Pan-solid Tumors
NCT06055166Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of fluzoparib in rectal cancer, non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC), Cervical Cancer (CC), sponsored by Chongqing University Cancer Hospital. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
rectal cancernon-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06055166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055166.